CEOCast this week mentions ZIVO writeup in Mergermarket but again does not expand on any specifics. Be nice for ZIVO management to provide shareholders with some tidbits or the article content.
Mergermarket is a paid service.
>>>>>>>>
Zivo Bioscience, Inc. (OTCQB: ZIVO), a biotech company that engages in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures, was featured in an article in Mergermarket, written by reporter Yiqin Shen. The article touched on some exciting possibilities involving its subsidiary WellMetris; a wholly owned unit of the Michigan based Biotech Company.
Zivo’s CEO, Andrew Dahl, said the WellMetris Profile will provide a testing package to determine the overall health and wellness of an individual, and can be applied in the workplace wellness and personal health nutrition spaces, which have $40 billion and $24 billion markets in the US. He also noted that once the product is launched, the major target clients should be health insurance companies, employers and wellness solutions providers, as the product allows them to better handle risk management and intervention by examining oxidative damage, total anti-oxidative status, and two indices of generalized, non-specific inflammation. Zivo finished the week at $0.08.
<<<<<<<<<
Wonder if he mentioned "which year" the Wellmetris Profile will be available ???? ROFLMAO !
Does seem that Dahl has stepped up the funding initiative more aggressively again with CEOCast personnel driving some of the activity.
Maybe closing in on some financing and/or another partner.
Tick tock tick tock ........
Amigo Mike
News 
Market Data 
Discover 
